Guidance for the 2024/25 financial year
September 11 2024 - 4:27PM
UK Regulatory
Guidance for the 2024/25 financial year
ANNOUNCEMENT NO. 272
11 September 2024
Guidance for the 2024/25 financial
year
ChemoMetec has today approved the annual report
for 2023/24, including the guidance for 2024/25, which is
considered inside information.
For 2024/25, ChemoMetec expects revenue in the
range of DKK 435-450 million (2023/24: DKK 407.4 million) and
EBITDA in the range of DKK 216-223 (2023/24: DKK 186.2
million).
The annual report for 2023/24, which is released
along with this announcement, sets out the underlying assumptions
applied in the preparation of the guidance for 2024/25 (p. 40).
Additional information
Martin Helbo Behrens, CEO
Tel.: (+45) 48 13 10 20
Kim Nicolajsen, CFO
Tel.: (+45) 48 13 10 20
About ChemoMetec A/S
ChemoMetec develops, manufactures and
markets instruments for cell counting and a wide range of other
measurements. ChemoMetec’s instruments are marketed to the
pharmaceutical, biotech and agricultural industries worldwide.
ChemoMetec’s customers include some of the world’s leading
pharmaceutical companies.
ChemoMetec was founded in 1997 and is listed
on Nasdaq OMX Copenhagen. For further information, go
to www.chemometec.com.
Chemometec AS (TG:CHY)
Historical Stock Chart
From Oct 2024 to Nov 2024
Chemometec AS (TG:CHY)
Historical Stock Chart
From Nov 2023 to Nov 2024